Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc. (CDT) reports that Craig Wigglesworth beneficially owns 1,258,042 shares of its common stock. This represented approximately 9.6% of the 13,043,866 shares outstanding as of August 31, 2026. He holds sole voting and dispositive power over all reported shares and disclaims beneficial ownership beyond his pecuniary interest.
CDT Equity Inc. (CDT) is registering 16,825,644 shares of common stock for resale by existing selling stockholders under a Form S-1, including shares issuable upon conversion of senior secured convertible notes and exercise of warrants. The company itself is not selling securities in this offering and will not receive proceeds from the resale of these shares.
The filing details multiple 2026 financing and acquisition-related transactions, notably senior secured convertible promissory notes and warrants issued to J.J. Astor & Co. and share issuances tied to acquiring an interest in Sarborg Limited. CDT Equity executed a 1-for-10 reverse stock split effective July 17, 2026, and its common stock trades on Nasdaq Capital Market under the symbol “CDT,” last reported at $0.63 on September 4, 2026.
CDT Equity is a data-driven biotech development company focusing on repositioned, clinical-stage therapeutic assets, including AZD1656 for autoimmune disorders and AZD5904 for idiopathic male infertility. The company reports substantial net losses, an accumulated deficit, going-concern uncertainty, and identified material weaknesses in internal control over financial reporting, while depending on future financings and successful clinical development to sustain operations.
CDT Equity Inc. amended its February 19, 2026 agreement to acquire a 20% equity interest in Sarborg Limited for $8,000,000, allowing $1,750,000 (or a mutually agreed amount) of that consideration to be paid in CDT common stock, subject to a 4.99% beneficial ownership limitation. CDT will apply Sarborg audit costs as credits against cash owed and pay the remaining cash consideration from its at-the-market program with minimum payments of $150,000 per month, with any balance due by May 31, 2027. On August 31, 2026, CDT issued 650,000 shares to Sarborg based on the August 28, 2026 share price as partial satisfaction of the stock component.
CDT also issued a senior secured convertible promissory note to J.J. Astor & Co. for a principal amount of $541,620, receiving $401,200 before fees and $375,002 in net proceeds, and repaid the note in full on September 4, 2026. In connection with this note, CDT issued warrants to purchase 237,000 CDT shares at an exercise price of $1.69 per share, exercisable immediately for five years; any warrant share issuance above 19.99% of current outstanding shares is subject to Nasdaq stockholder-approval requirements.
CDT Equity Inc. (CDT) has a significant shareholder group led by Mark Taylor of New Zealand, who may be deemed to beneficially own 1,258,042 shares of Common Stock through Prospect Capital Securities Ltd and Prospect Finance Ltd. These shares represented 9.6% of CDT Equity’s outstanding Common Stock as of August 31, 2026, based on 13,043,866 shares outstanding provided by the company. Prospect Capital and Prospect Finance each directly hold 629,021 shares, or 4.8% of the class. Mr. Taylor, as sole director and sole shareholder of both entities, has shared voting and dispositive power over all 1,258,042 shares and disclaims beneficial ownership except to the extent of his pecuniary interest.
CDT Equity Inc. (symbol: CDT) is the issuer of record for a Form 4 filing submitted to the SEC.
CDT Equity Inc. (symbol: CDT) is the issuer of record for a Form SCHEDULE 13D/A filing submitted to the SEC.
CDT Equity Inc. (CDT) reports that stockholders at its 2026 Annual Meeting approved the issuance of common shares underlying pre-funded warrants held by certain former Sarborg Limited investors. Those investors subsequently exercised all pre-funded warrants on a cashless basis, and CDT Equity issued 12,131,122 shares of common stock.
After these exercises, issuances under the at-the-market offering program, and other recent issuances, CDT Equity had 13,693,866 common shares issued and outstanding as of August 31, 2026. Based on the August 31, 2026 closing share price, market capitalization was approximately $23.0 million, while stockholders’ equity, as reported for the quarter ended June 30, 2026, was approximately $103 million. The company states that, as a result, it no longer has any outstanding deficiencies with The Nasdaq Stock Market LLC.
CDT Equity Inc. (CDT) appointed James Bligh as Chief Executive Officer effective August 31, 2026; he will continue as Chief Financial Officer and a director. Under a new employment agreement, he receives a $600,000 annual base salary and is eligible for an annual cash bonus targeted at 50% of base salary.
Former CEO and director Dr. Andrew Regan resigned effective the same date, receiving $50,000 per month in severance for six months, and the board size decreased from five to four members. Stockholders at the August 28, 2026 annual meeting elected five directors, ratified Carr, Riggs & Ingram, L.L.C. as auditor, and approved amendments authorizing one or more reverse stock splits within a range between 1‑for‑2 and, in the aggregate, not more than 1‑for‑500, at the board’s discretion.
Stockholders also approved share issuances under a senior secured convertible note and warrant issued to J.J. Astor & Co., and the issuance of up to 12,131,770 shares of common stock upon exercise of certain pre‑funded warrants, each under Nasdaq Listing Rule 5635, along with an adjournment proposal supporting these items.
CDT Equity Inc. (symbol CDT) has a group of related investors reporting beneficial ownership of its common stock. Primary Development Fund (Cayman) SPC, E2 Trust, E3 Fund SP and IALC Trustees SA together may be deemed to beneficially own 23,912 shares of CDT common stock after a 1-for-10 reverse stock split effected on July 20, 2026.
The group’s holdings represent 2.97% of CDT’s common stock, based on 786,670 shares outstanding as of August 12, 2026. Voting and dispositive powers over these 23,912 shares are reported as shared among the four reporting persons, with no sole voting or dispositive power for any of them.
CDT Equity Inc. (CDT) has a new Schedule 13G showing that a group of related investment entities collectively report beneficial ownership of a minority stake in the company’s common stock. Primary Development Fund (Cayman) SPC, E2 Trust, E3 Fund SP, and IALC Trustees SA together report beneficial ownership of 5.3% of CDT common stock. This is based on 786,670 CDT shares outstanding as of August 12, 2026, after the company’s 1-for-25 reverse stock split on March 26, 2026 and 1-for-10 reverse stock split on July 20, 2026.